Effects of iron deprivation on multidrug resistance of leukemic K562 cells

Dingzhu Fang1, Yixiao Bao, Xiaobin Li

  • 1Department of Pediatrics, Affiliated XinHua Hospital, Jiaotong University, Shanghai, China.

Chemotherapy
|February 27, 2010
PubMed
Abstract

Insights

Iron deprivation significantly reduces multidrug resistance (MDR) by downregulating MDR1 gene and P-glycoprotein (P-gp) expression and function in K562 leukemia cells. This suggests DFO could enhance chemotherapy efficacy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Multidrug resistance (MDR) significantly hinders chemotherapy effectiveness.
  • Existing strategies to overcome MDR have yielded limited success.
  • Iron deprivation has been implicated in downregulating MDR genes.

Purpose of the Study:

  • To investigate the impact of iron deprivation on MDR and related genes, specifically MDR1, EGR1, H-Fn, and P-gp.
  • To explore the relationship between iron levels and MDR in the K562 leukemic cell line.

Main Methods:

  • K562 cells were treated with TPA and either FeCl3 or the iron chelator DFO.
  • mRNA levels of MDR1, EGR1, and H-Fn were quantified using RT-PCR.
  • P-gp protein expression and function were assessed via immunohistochemistry and daunorubicin exclusion assays, respectively.

Main Results:

  • DFO treatment markedly decreased intracellular iron levels.
  • Significant reductions were observed in MDR1 mRNA (~70%), H-Fn mRNA (~50%), and P-gp protein (~30%).
  • DFO also diminished P-gp pump function, as indicated by increased daunorubicin retention.

Conclusions:

  • A strong correlation exists between iron deprivation and reduced MDR1/P-gp expression and function.
  • Deferoxamine (DFO) shows potential as an adjunct therapy to improve clinical outcomes in chemotherapy.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...